CURE

Key GI Cancer Advances from the 2026 ASCO Symposium

This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...
Medscape

Doublet Immunotherapy Disappoints in Gastric Cancer Study

BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric ...
ascopubs.org

A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized ...

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO conference.
ascopubs.org

Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations. This is an ASCO Meeting Abstract from ...
Cure Today

Three Months of Chemotherapy May Be Superior To Six in Colorectal Cancer

Six months of chemotherapy in low-risk stage 3 colorectal cancer patients increases neuropathy compared to three months. IDEA collaboration found similar survival outcomes between three and six months ...